Quarterly ResultMay 12, 2026, 08:22 AM
AtaiBeckley Q1 Net Loss $29.8M; BPL-003 Phase 3 On Track
AI Summary
AtaiBeckley Inc. reported a net loss of $29.8 million for the first quarter of 2026, with R&D and G&A expenses increasing year-over-year. The company announced that its BPL-003 Phase 3 pivotal program for treatment-resistant depression is on track to initiate in Q2 2026, with topline readouts expected in early 2029. Additionally, VLS-01 Phase 2 topline results are anticipated in Q4 2026, and EMP-01 Phase 2a data showed positive results in Social Anxiety Disorder. AtaiBeckley's cash position of $209.9 million is expected to fund operations into 2029.
Key Highlights
- Cash and cash equivalents were $209.9 million as of March 31, 2026, providing a runway into 2029.
- BPL-003 Phase 3 pivotal program for treatment-resistant depression (TRD) is on track to initiate in Q2 2026.
- VLS-01 Phase 2 topline results for TRD are anticipated in Q4 2026.
- EMP-01 Phase 2a trial demonstrated consistent improvements in Social Anxiety Disorder.
- Net loss attributable to stockholders was $29.8 million for the first quarter ended March 31, 2026.
- Research and development expenses increased to $17.4 million in Q1 2026 from $11.3 million in Q1 2025.
- General and administrative expenses rose to $14.4 million in Q1 2026 from $10.6 million in Q1 2025.
- Michael Faerm was appointed Chief Financial Officer, effective March 9, 2026.